Prognostic Value of High-sensitivity Troponin I in Patients with Septic Shock: A Prospective Observational Study

Ali Jendoubi, Salma Jerbi, Elaa Maamar, Ahmed Abbess, Zied Samoud, Lamia Kanzari, Ilhem Boutiba, Salma Ghedira, Mohamed Houissa

ABSTRACT

Background: Myocardial dysfunction is one of the mechanisms involved in the pathophysiology of septic shock. The role of troponin as a surrogate of myocardial injury in septic shock is still debated. The aim of this study was to assess the prognostic value of high-sensitivity cardiac troponin I (hs-cTnI) assay in predicting 28-day mortality in patients with septic shock.

Materials and Methods: Prospective study including 75 patients with septic shock admitted to a medico-surgical ICU from January to December 2017. Patients under the age of 18 years, known pregnancy and patients in post–cardiac arrest were excluded. Clinical and demographic data including age, gender, comorbidities, SAPS II and SOFA scores were collected. Hs-cTnI was measured soon after admission and 12, 24, 48 and 72 after. Receiver operating characteristic (ROC) analysis was performed to identify the most useful troponin I cut-off level for the prediction of 28-day mortality. A p < 0.05 was considered significant.

Results: Seventy-five (M/F = 53/22) patients with septic shock were included in the study. The median SOFA and SAPS II scores were 10 and 42, respectively. The median duration of mechanical ventilation was 8 days and the median length of ICU stay was 11 days. The 28-day mortality was 54.6%. We found a high prevalence (47%) of elevated hs-cTnI in patients with septic shock. Median hs-cTnI on admission in the whole group was 36 ng/L. The 28-day mortality was found to be related to age (p < 0.001), SAPS II score (p = 0.001), mean arterial pressure (p = 0.038), lactate (p < 0.001) and glomerular filtration rate (p < 0.001).

Hs-cTnI levels were significantly higher in non-survival group than survival one at all time points: H12 (p = 0.006), H24 (p = 0.003), H48 (p = 0.005) and H72 (p = 0.001). In multivariate analysis, hs-cTnI at H72 was independently associated with 28-day mortality.

Conclusion: Hs-cTnI elevation at 72 hours was associated with 28-day mortality in septic shock patients.

Keywords: High-sensitivity cardiac troponin, Mortality, Prognosis, Septic shock

INTRODUCTION

Septic shock is a leading cause of mortality in intensive care units (ICUs). Despite recent advances in the management of septic shock, mortality rates have remained remarkably high, ranging from 30 to 50%. Myocardial dysfunction is one of the mechanisms involved in the pathophysiology of septic shock. Septic myocardial dysfunction is usually defined as global (systolic and diastolic) but reversible biventricular dysfunction. An incidence ranging from 20 to 60% has been reported in the first 3 days after the onset of septic shock. Ventricular function generally returns to normal within 7–10 days. The pathophysiology of this dysfunction is complex and not completely understood. It involves, in addition to circulatory abnormalities, alterations in coronary blood flow, circulating depressant factors, microvascular dysfunction, abnormalities of beta-adrenergic signal transduction, apoptotic phenomena and calcium dysregulation. Cardiac troponins are specific biomarkers of myocardial cell injury and their role for risk stratification in acute coronary syndromes is well established. The role of troponin in risk stratification of sepsis is still debated. A new generation of highly sensitive troponin assays has recently been developed that allow the detection of concentrations 10 times lower than those measureable with conventional assays. The aim of this study was to determine the association between high-sensitivity cardiac troponin I (hs-cTnI) elevation and 28-day mortality in patients with septic shock.

How to cite this article: Jendoubi A, Jerbi S, Maamar E, Abbess A, Samoud Z, Kanzari L, et al. Prognostic Value of High-Sensitivity Troponin I in Patients with Septic Shock: A Prospective Observational Study. Indian J Crit Care Med 2019;23(7):320–325.

Source of support: Nil

Conflict of interest: None

MATERIALS AND METHODS

After approval of the Local Ethics Committee, a single center prospective observational cohort study was conducted in a 12-bed mixed surgical and medical ICU over a 12-month period, from 1st January 2017 to 31st December 2017. This study included consecutive septic shock adult patients (18 years old or more) admitted to the ICU. Septic shock was defined as sepsis with hypotension despite initial volume resuscitation of 30 mL/kg body weight in accordance with Septic Shock: A Prospective Observational Study.
with the American College of Chest physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference Committee. Patients under the age of 18 years, known pregnancy and patients in post–cardiac arrest were excluded.

Baseline clinical variables including age, gender, body mass index (BMI), cause of sepsis and preexisting comorbidities were collected. The severity of disease was assessed by SAPS II (Simplified Acute Physiology Score) and the SOFA (Sepsis-related Organ Failure Assessment) scores. At ICU admission, clinical and biological parameters including heart rate (HR), mean arterial pressure (MAP), complete blood count, C-reactive protein (CRP), serum creatinine, estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease MDRD formula, total bilirubin, albumin, lactate, prothrombin time (International Normalized Ratio) and arterial blood gas analysis were also collected. Lengths of mechanical ventilation and ICU stay were recorded, ICU and 28-day mortality were assessed. Patients were subjected to transthoracic echocardiography (TTE) at study inclusion and cardiac output measurement was performed.

Biochemical analysis: We measured troponin concentrations in plasma soon after admission in ICU and 12, 24, 48 and 72 hours after; using a high-sensitivity troponin I assay (Abbott ARCHITECT STAT, Abbott Laboratories). The recommended cut-off value for an elevated cardiac troponine is the 99th percentile of a control reference group at a precision level ≤10% coefficient of variation. The high-sensitivity assay is reported in units of ng/L. The 99th percentile upper reference limit (URL) for this test is 34 ng/L for men and 16 ng/L for women. The limit of detection is 1.9 ng/L and the interassay coefficient of variation is <10% at 4.7 according to the manufacturer’s specification.

Outcomes: The primary study outcome was 28-day mortality. Predefined secondary outcomes were: duration of mechanical ventilation and length of ICU and hospital stay.

Statistical analysis: Continuous variables are expressed as mean ± standard deviation or median (interquartile range). Categorical variables were compared using χ² analysis, and continuous variables with normal distributions were compared using the Student’s t test. The Mann–Whitney U test was used to compare continuous variables with a skewed distribution. Discrimination between hospital survivors and non-survivors was evaluated by receiver operating characteristic (ROC) curve analysis.

Variables with a p value < 0.02 on bivariate analysis were included in the logistic regression model for multivariate analysis of 28-day mortality. Adjusted ORs were calculated using a logistic regression model. All statistical analyses were performed using the Statistical Package for the Social Sciences 18.0 software (SPSS Inc., Chicago, IL, USA). p values less than 0.05 were considered statistically significant.

Results
Seventy-five patients with septic shock were included in the study. Table 1 shows the baseline characteristics of the entire cohort. Thirty five (47%) patients had elevated troponin I levels. The 28-day mortality was 54.6% (41/75).

Characteristics of the patients according to 28-day mortality are summarized in Table 2. Survivors were significantly younger than non-survivors and had significantly lower severity of illness (SAPS II score). In the univariate analysis, 28-day mortality was found to be related to low MAP (p = 0.038) and high lactate level (p <0.001).

![Image](https://example.com/image.png)

### Table 1: Baseline characteristics of the study population

| Variables                     | Values (n = 75) |
|-------------------------------|-----------------|
| Age (years) median (min-max)  | 57(18-93)       |
| Male gender n (%)             | 53 (70%)        |
| SAPSII median [IQR]           | 42 [34 – 53]    |
| SOFA median [IQR]             | 10 [8 – 11]     |

**Comorbidities**

|                   |                 |
|-------------------|-----------------|
| Diabetes mellitus n (%) | 22/75 (29.3%)   |
| Hypertension n (%)       | 16/75 (21.3%)   |
| Atrial fibrillation n (%) | 8/75 (10.7%)     |
| Dyslipidemia n (%)        | 4/75 (5.4%)     |

**Laboratory tests and ABG analysis**

|                   |                 |
|-------------------|-----------------|
| CRP (mg/L) mean ± SD | 194.5 ± 113.8   |
| Creatinine clearance MDRD (mL/min) mean ± SD | 87.1 ± 50.9 |
| Leucocytes x10³/L mean ± SD | 18.02 ± 7.99   |
| Platelet count x10⁹/L mean ± SD | 222.11 ± 144.5 |
| PaO₂/FiO₂ mean ± SD | 248.47 ± 15.97  |

**Macro- and microcirculatory variables**

|                   |                 |
|-------------------|-----------------|
| HR (bpm) mean ± SD | 107.08 ± 24.53  |
| MAP (mm Hg) mean ± SD | 78.81 ± 11.88  |
| Cardiac index l/min/m² mean ± SD | 2.48 ± 0.77    |
| Blood Lactate level (mmol/L median [IQR]) | 1.9 [1.1 – 3.2] |

**High-sensitivity cardiac troponin I concentrations**

|                   |                 |
|-------------------|-----------------|
| Hs-cTnl H0 ng/L median [IQR] | 36 [12 – 108]  |
| Hs-cTnl H12 ng/L median [IQR] | 43 [13 – 342] |
| hs-cTnl H24 ng/L median [IQR] | 42 [18 – 253] |
| hs-cTnl H48 ng/L median [IQR] | 51 [10 – 124] |
| hs-cTnl H72 ng/L median [IQR] | 21 [9 – 94]    |

**Norepinephrine µg/kg/min median [IQR]**

|                   |                 |
|-------------------|-----------------|
| 0.44 [0.22 – 0.69] |

**Outcome variables**

|                   |                 |
|-------------------|-----------------|
| Length of ICU stay days median [range] | 11 [5 – 20]    |
| Duration of Mechanical Ventilation days median [IQR] | 8 [3 – 14]     |

28-day mortality n (%) 41/75 (54.6%)

Data are presented as means ± standard deviation (SD), medians (Interquartile range Q1–Q3) or absolute numbers (percentage). SAPS II, Simplified Acute Physiology Score. SOFA: Sequential Organ Failure Assessment; MAP, Mean arterial pressure; HR, Heart rate; ABG, Arterial Blood Gasses.

The eGFR was significantly lower in non-survivors than in survivors (p <0.001). Baseline median hs-cTnl levels were not significantly higher in non-survivors than survivors (p = 0.126) but the serial measurements over a 72-hour period showed that hs-cTnl levels were significantly higher in non-survival group than survival group at all time points H12 (p = 0.003), H48 (p = 0.005) and H72 (p = 0.001).

Our patients were then categorized into 2 groups: hs-cTnl (+) positive group (serum hs-cTnl level, M: ≥34 ng/L; F: ≥16 ng/L) and hs-cTnl (−) negative group (serum hs-cTnl level, M: <34 ng/L; F: <16 ng/L). Baseline characteristics of the cohorts with and without hs-cTnl elevation are detailed in Table 3. There were no significant differences between two groups at baseline regarding the age, MAP, cardiac index, vasopressor or ventilatory requirements and lactate levels. The eGFR was significantly lower in the hs-cTnl + positive group (p = 0.017).
Table 2: Characteristics of the study patients according to 28-day survival status

| Variables                        | Non-survivors (n = 41) | Survivors (n = 34) | p value |
|----------------------------------|-------------------------|--------------------|---------|
| Age (years) median (min-max)     | 60(26-93)               | 40(18-90)          | <0.001  |
| SAPSII median [IQR]              | 49 [37 – 63]            | 36 [29 – 45]       | 0.001   |
| SOFA median [IQR]                | 10 [8 – 12]             | 10 [8 – 11]        | 0.213   |

Laboratory tests and ABG analysis

| Variables                        | Non-survivors (n = 41) | Survivors (n = 34) | p value |
|----------------------------------|-------------------------|--------------------|---------|
| CRP (mg/L) median [IQR]          | 218 [114 – 285]         | 166 [86 – 259]     | 0.213   |
| Creatinine clearance MDRD (mL/min) median [IQR] | 54 [29 – 106] | 110 [85 – 135] | 0.001 |
| Leucocytes (x10^9/L) mean ± SD   | 19.07 ± 8.50            | 16.44 ± 7.22       | 0.188   |
| Platelet count (x10^9/L) mean ± SD | 225.32± 156.21        | 216.87± 136.65     | 0.007   |
| PaO2/FiO2 median [IQR]           | 220 [139 – 308]         | 233 [176 – 384]    | 0.333   |

Macro- and microcirculatory variables

| Variables                        | Non-survivors (n = 41) | Survivors (n = 34) | p value |
|----------------------------------|-------------------------|--------------------|---------|
| HR (bpm) median [IQR]            | 111 [92 – 128]          | 102 [83 – 113]     | 0.076   |
| MAP (mmHg) median [IQR]          | 75 [69 – 85]            | 84 [73 – 90]       | 0.038   |
| Cardiac index l/min/m^2 median [IQR] | 1.9 [1.4 – 3.1]   | 2.5 [1.9 – 3.1] | 0.179 |
| Blood Lactate level (mmol/L) median [IQR] | 2.5 [1.7 – 3.7] | 1.1 [0.8 – 1.9] | <0.001 |
| Norepinephrine µg/kg/min median [IQR] | 0.53 [0.18 – 0.88] | 0.43 [0.22 – 0.62] | 0.211 |

| Variables                        | Non-survivors (n = 41) | Survivors (n = 34) | p value |
|----------------------------------|-------------------------|--------------------|---------|
| 28-day mortality (NS/S)          | 25/15                   | 16/19              | 0.070   |
| Age (years) median (min-max)     | 57(18-93)               | 57(25-90)          | 0.838   |
| SAPSII median [IQR]              | 45 [34 – 55]            | 38 [29 – 50]       | 0.136   |
| SOFA median [IQR]                | 10 [8 – 12]             | 10 [8 – 11]        | 0.825   |
| CRP (mg/L) median [IQR]          | 207[100 – 269]          | 197 [106 – 277]    | 0.942   |
| eGFR MDRD (mL/min) median [IQR]  | 54 [33 – 107]           | 99 [51 – 135]      | 0.017   |
| Leucocytes (x10^9/L) mean ± SD   | 19.11 ± 8.30            | 16.91 ± 7.34       | 0.164   |
| Platelet count (x10^9/L) mean ± SD | 226.28± 141.42         | 184.33± 99.77      | 0.201   |
| PaO2/FiO2 median [IQR]           | 243 [147 – 355]         | 234 [160 – 314]    | 0.778   |
| HR (bpm) median [IQR]            | 110 [92 – 125]          | 102 [89 – 120]     | 0.257   |
| MAP (mm Hg) median [IQR]         | 80 [70 – 88]            | 81 [72 – 87]       | 0.585   |
| Cardiac index l/min/m^2 median [IQR] | 1.9 [1.4 – 3.1]   | 2.5 [1.9 – 3.1] | 0.179 |
| Blood lactate level (mmol/L) median [IQR] | 2.5 [1.9 – 3.1] | 2.4 [1.9 – 2.9] | 0.683 |
| Norepinephrine µg/kg/min median [IQR] | 0.44 [0.19 – 0.79] | 0.45 [0.27 – 0.66] | 0.696 |

The prediction of mortality was assessed using the area under the ROC curve (AUC). The AUC for hs-cTnI at admission was 0.61 [95% CI, 0.47–0.75; p = 0.126] (Fig. 1). The AUC value of 0.61 suggests the admission troponin level is poorly discriminatory when used to predict the 28-day mortality among patients with septic shock. We also compared the discriminatory power between hs-cTnI values at different time points (H12, H24, H48 and H72) for predicting 28-day mortality. The best cut-off values for troponin levels for mortality, obtained from ROC curves (Fig. 1), are shown in Table 4. A troponin level greater than 17 ng/l at H72 was the strongest predictor of 28-day mortality, with an odds ratio of 8.5.

Based on the data of all the patients, the following variables were selected (P ≤0.02) by the stepwise logistic regression
Prognostic Value of High-Sensitivity Troponin I in Patients with Septic Shock: A Prospective Observational Study

In the present study, we found a high prevalence (47%) of elevated hs-cTnI in patients with septic shock. The serial measurements of cardiac troponins over a 72-hour period showed that hs-cTnI levels were significantly higher in non-survival group than survival group at all time points H12, H24, H48 and H72. In multivariate analysis, hs-cTnI at H72 was independently associated with 28-day mortality, with a hazard ratio of 16.8 (95% confidence interval [CI] 3.417-82.603; p = 0.001).

Recently, several studies have also reported detectable troponin levels in septic patients, but their predictive value has not been firmly established. The reasons for circulating cardiac troponin elevation in severe sepsis and septic shock are still debated. Troponin release in sepsis does not necessarily indicate cardiomyocyte necrosis, but could also be a result of increased cell permeability and the release of troponin degradation products through the cell membrane in non-necrotic cardiomyocytes.12,13

A close association between hs-cTnT and NT-proBNP levels in septic shock was reported in the ALBIOS Trial14 highlighting the value of troponin in simultaneous assessment of myocardial function and circulatory status. In a recent study by Landesberg and colleagues,15 left ventricular diastolic dysfunction and right ventricular dilatation were found to be strongly associated with hs-cTnT positivity and mortality. Ver Elst et al.16 noted that 78% of cTnI+ patients had reduced left ventricular ejection fraction compared with 9% of cTnI− individuals. Fernandes et al.17 observed similar findings. No differences in the coagulation parameters analyzed with rotational thrombelastometry were found between cTnI positive and negative patients with systemic inflammatory response syndrome (SIRS), sepsis or septic shock.18

Several pathophysiological mechanisms other than thrombus-associated myocardial damage could play a major role, including reversible myocardial membrane leakage and/or cytokine mediated apoptosis in these patients. It has been suggested that sepsis-induced myocardial dysfunction involves pro-inflammatory cytokines including tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6, nitrite oxide, alteration of beta-adrenergic receptors, apoptosis and calcium abnormalities particularly a decreased myocardial fibers sensibility.5

In our study, the prevalence of increased cardiac troponin I levels was 47%. In a heterogeneous population of patients with sepsis, severe sepsis, and septic shock, the incidence of elevated troponin ranged from 55% to 85%.12,17,21,23 In studies involving patients with septic shock, there was an incidence of elevated cardiac troponin I ranging from 43% to 80%.16,24,25 In a meta-analysis involving 13 studies and 1227 patients with sepsis, Bessière and colleagues reported a prevalence of 61% of elevated troponin in patients.8

There are only a few studies in the literature that have reported increased levels of hs-cTnI in patients with septic shock. In a post hoc analysis of a cohort of 995 patients with severe sepsis or septic shock participating in the ALBIOS trial, Masson S. et al.18 showed high levels of hs-cTnT in up to 84.5% of septic shock patients. In this predefined substudy, the hs-cTnT levels were twice as high in patients with shock as compared to those with severe sepsis without shock. In a recent study published in February 2018 by Frencken et al.,26 the researchers performed daily measurements of hs-cTnI in a large cohort of 1256 patients hospitalized in ICU with sepsis. The authors found that 60% of the subjects had a troponin level above the upper reference limit of the test (26 ng/L) on day 1, and an additional 82 (7%) developed raised concentrations within the first 4 days in the ICU.

The main finding in our study is the close association between increased hs-cTnI concentrations at 72 hours and 28-day mortality.

Table 4: Best cutoff values of troponin that were obtained from ROC curves for mortality

| Variable | Cutoff (ng/l) | OR | Se (%) | Sp (%) | p |
|----------|--------------|----|--------|--------|---|
| hs-cTnI H12 | 0.748 (0.548-0.948) | 50 | 5.8 | 70 | 76 | 0.061 |
| hs-cTnI H24 | 0.773 (0.566-0.980) | 30 | 5.3 | 80 | 62 | 0.039 |
| hs-cTnI H48 | 0.782 (0.583-0.980) | 40 | 6.4 | 82 | 65 | 0.033 |
| hs-cTnI H72 | 0.807 (0.614-0.999) | 17 | 8.5 | 63 | 81 | 0.020 |

Hs-cTnI, high-sensitivity cardiac troponin I; AUC, area under the ROC curve

Table 5: Multivariable logistic regression analysis of variables for mortality

| Variable | OR | 95% Confidence interval | p |
|----------|----|-------------------------|---|
| Age | 1.04 | 0.991 | 1.081 | 0.119 |
| SAPS II | 0.20 | 0.019 | 2.112 | 0.182 |
| Lactate | 3.82 | 0.678 | 21.530 | 0.128 |
| eGFR | 0.99 | 0.975 | 1.017 | 0.690 |
| Hs-cTnI at H72 | 16.80 | 3.417 | 82.603 | 0.001 |

SAPS II, standardized index of gravity; OR, Odds Ratio; Hs-cTnI, high-sensitivity cardiac troponin I; eGFR, estimated glomerular filtration rate

Fig. 1: Comparison of ROC curves between hs-cTnI values at different time points
Prior studies on sepsis and septic shock have presented conflicting data on the association of clinical outcomes with troponin elevation. Positive studies: troponin levels were independently associated with mortality after sepsis in 2 recent meta-analyses. In a large retrospective study of 598 patients, John J. et al. found that elevated cTnI was an independent prognosticator of 28-day mortality in severe sepsis patients (OR: 2.02; 95% CI: 1.15-3.54; \( p < 0.05 \)). In another retrospective cohort study conducted in Mayo Clinic, USA, and involving 944 patients with severe sepsis and septic shock, the authors found that elevated admission cTnT was associated with higher short- and long-term mortality (in-hospital mortality: OR 1.4; \( p = 0.04 \); 1-year mortality: OR 1.3; \( p = 0.008 \)).

Previous studies have demonstrated that myocardial injury is predictive of in hospital or 28-day mortality in patients with severe sepsis or septic shock. In a meta-analysis of 17 studies with total sample size of 1857 patients, the authors found that elevated troponin was significantly associated with mortality (Risk ratio: 1.91; 95% CI: 1.65-2.22; \( p < 0.05 \)). Recent findings from a large scale prospective cohort study in the Netherlands (\( n = 1124 \) septic patients), Frencken et al. found that hs-cTnI concentrations were elevated in 673 (60%) subjects on day 1, and 755 (67%) ever had elevated levels in the first 4 days.

Negative studies: In contrast, several studies have not found elevated troponin to be an independent predictor of mortality in septic patients. In a study of a cohort of 159 patients with bacteremia reported that cTnI measured with a conventional assay is a univariate, but not an independent predictor of outcome. In a subgroup of 207 patients from FINNSEPIS trial (a large prospective observational cohort study of the incidence and prognosis of sepsis in 24 intensive care units (ICUs) in Finland), the level of hs-cTnI on inclusion was higher in hospital non-survivors than survivors \( (p = 0.047) \), but hs-cTnT level was not an independent predictor of in-hospital mortality.

Study limitations: Several limitations in our study need to be mentioned: The first is that we conducted a single centre study. Second, the generalisability of our findings is limited by the small sample size. Third, and most importantly, we have not reported electrocardiographic changes and have not assessed the cardiac function by echocardiography (evaluation of the left and right ventricular systolic and diastolic function).

Implications for practice: Our results suggest questions regarding the role of high-sensitive cardiac troponin I assays during septic shock management and highlight the need for further studies to identify which subgroup of septic patients needs serial troponin testing and eventually requires aggressive management of shock and to evaluate prognostic value of hs-cTnI for long-term outcomes including all-cause mortality and major cardiovascular events at long-term (>1 year) follow-up. The application of this biomarker-based approach could help stratify risk in the emergency department.

References

1. Levy MM, Rhodes A, Phillips GS, Townsend SR, Schorr CA, Beale R et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Crit Care Med. 2015;43:3–12.
2. Antonucci E, Fiaccadori E, Donadello K, Taccone FS, Franchi F, Scalfetta S. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care. 2014;29:500–511.
3. Vieillard-Baron A. Septic cardiomyopathy. Ann Intensive Care. 2011;1:6.
4. Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36:1701–1706.
5. Tavernier B, Mebazaa A, Mateo P, Sys S, Ventura-Claper R, Vekslser V. Phosphorylation-dependent alteration in myofilament Ca2+-sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med. 2001;163:362–367.
6. Bernardin G, Strosberg AD, Bernard A, Mattei M, Marullo S. Beta-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med. 1998;24:1315–1322.
7. Morrow DA, Cannon CP, Jesse RL, Newby LK, Raykilde J, Storrow AB, et al. Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:356–375.
8. Bessière F, Khenifer S, Dubourg J, Durieu I, Lega J. Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med. 2013;9:1181–1189.
9. Sheynin O, Davies O, Duan W, Perez X. The prognostic significance of troponin elevation in patients with sepsis: a meta-analysis. Heart Lung. 2015;44:75–81.
10. Giannitsis E, Kurz K, Hallemeyer K, Jaarsch A, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56:254–261.
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapeutics in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest. 2009;136:e28.
24. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. 1999;27:1775–1780.
25. Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95:13–17.
26. Frencken JF, Donker DW, Spitoni C, Koster-Brouwer ME, Soliman IW, Ong DSY et al. Myocardial injury in patients with Sepsis and its association with long-term outcome. Circ Cardiovasc Qual Outcomes. 2018;11:e004040.
27. Vallabhajosyula S, Sakhuja A, Geske JB, Kumar M, Poterucha JT, Kashyap R, et al. Role of admission troponin-T and serial troponin-T testing in predicting outcomes in severe sepsis and septic shock. J Am Heart Assoc. 2017;6:e005930.
28. Furian T, Aguiar C, Prado K, Ribeiro RV, Becker L, Martinelli N, et al. Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality. Journal of critical care. 2012; 27:319.
29. Scott EC, Ho HC, Yu M, Chapital AD, Koss W, Takanishi DM Jr. Preexisting cardiac disease, troponin I elevation and mortality in patients with severe sepsis and septic shock. Anaesth Intensive Care. 2008;36:51–59.
30. Brivet FG, Jacobs FM, Colin P, Prat D, Grigoriu B. Cardiac troponin level is not an independent predictor of mortality in septic patients requiring medical intensive care unit admission. Crit Care. 2006;10:404.
31. Kalla C, Raveh D, Algur N, Rudensky B, Yinnon AM, Balkin J. Incidence and significance of a positive troponin test in bacteremic patients without acute coronary syndrome. Am J Med. 2008;121:909–915.
32. Karlsson S, Varpula M, Ruokonen E, Pettila` V, Parviainen I, Ala-Kokko Ti, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435–443.
33. Rasjø H, Varpula M, Hauge TA, Karlsson S, Ruokonen E, Pettilia V, et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med. 2011;37:77–85.